New Anticlotting Drug May Extend Heart Patients' Lives
Study Shows Xarelto Helps Treat People Who Had Heart Attacks or Chest Pain
Xarelto for Acute Coronary Syndrome continued...
Overall, 9% of those given Xarelto had a heart attack or stroke or died from heart disease or stroke vs. 11% given standard therapy alone. This translates to a 16% lower risk of suffering one of these events if you take Xarelto.
People taking the very low dose were also more likely to still be alive two years later. A total of 3% died vs. 5% in the standard treatment group.
One death would be prevented if 56 people on standard anticlotting therapies were also given very low-dose Xarelto twice daily for two years, says researcher C. Michael Gibson, MD, of Harvard Medical School. Gibson has received consulting fees from Johnson & Johnson.
But people taking Xarelto were nearly four times more likely to have serious bleeding: 2.1% vs. 0.6% on placebo. About one-third were bleeds into the brain, which can be disabling. Most of the rest were gastrointestinal bleeds.
However, there was no increase in fatal bleeding or other side effects with the new drug. All patients benefited from the new drug, including the elderly and people with diabetes, Gibson says.
Other Drugs for Acute Coronary Syndrome
Drugs already used to treat ACS, including Brilinta, Effient, and Plavix, block platelets (blood components involved in clotting) in the blood from sticking together and forming clots. Xarelto affects clotting in a different way, by blocking a protein involved in clotting.
Pradaxa and Eliquis are from the same family of drugs as Xarelto. Although Eliquis failed to prevent heart attacks and deaths while causing more serious bleeding in a recent study, Armstrong tells WebMD that is likely because too high a dose was tested.
The findings were generally met with enthusiasm, although questions remain.
Doctors have been searching for better anticlotting drugs for heart patients for years, but efforts typically failed because of too much bleeding, Matthew T. Roe, MD, and E. Magnus Ohman, MD, both of Duke University Medical Center in Durham, N.C., write in an editorial accompanying the study.
Xarelto and drugs similar to it may represent "a new standard of [anticlotting] treatment in ACS," Armstrong says.
AHA President Gordon Tomaselli, MD, head of cardiology at Johns Hopkins, was more tempered. "I'm cautiously optimistic that [Xarelto] will find a niche in the treatment of ACS," he tells WebMD.
Doctors need better ways of predicting which patients are at risk for drug-related bleeding, Tomaselli says.
Among the questions that remain are whether patients who at the highest risk of another heart attack or dying would benefit from taking Xarelto.